Navigation Links
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
Date:9/24/2009

w in coronary arteries unless their rupture results in a clot.

Among the findings of the 700-patient study, researchers were able to identify the common characteristics of lesions that put patients at highest risk for future cardiac events by using advanced imaging called virtual histology intravascular ultrasound (VH(R) IVUS) and standard angiography. Going forward, investigators will now have access to more than 40,000 datapoints derived from 150 variables within each of the patients, far beyond the level of assessment of previous interventional studies.

"While the prognosis of patients with acute coronary syndromes undergoing successful stenting and treated with contemporary medical therapy is favorable, we are now able to identify those lesion types with a significantly increased likelihood of causing future cardiovascular events," Stone said.

The PROSPECT study recruited patients who were in need of a PCI (percutaneous coronary intervention) to treat a heart attack or threatened heart attack. Patients consented to collection of additional data as follow-up to their procedure, including VH IVUS imaging and standard angiography. PROSPECT collected data about characteristics of vulnerable plaque lesions that were present but not causing symptoms at the time of the procedure. The goal was to correlate lesion characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events, potentially paving the way for physicians to identify and treat at-risk patients before a heart attack occurs.

Study Findings

In the study, approximately 20 percent of the patient population experienced a major adverse cardiac event (cardiac death, cardiac arrest or heart attack) within three years of enrollment. Half of these events can be attributed to the original "culprit" lesions (those treated with PCI) and half to previously untreated,
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... -- Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... the fourth quarter and year ended December 31, 2014. ... less than $0.01 per share, on revenues of $8,018,000 ... with net income of $195,000, or $0.01 per share, ... 2013. The substantial increase in fourth quarter 2014 revenue ...
(Date:3/6/2015)... , March 6, 2015  AbbVie (NYSE: ... Health Care Conference on Thursday, March 12, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
(Date:3/6/2015)... , Alemania, 6 de marzo de 2015 /PRNewswire/ ... soluciones de gestión empresarial de imagen médica, fortalece ... el nombramiento de Randolph Sternberg como ... como director de operaciones. Logo ... Sternberg será responsable de las ventas y ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 2Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 4Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 5TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3
... 5, 2012 Cogmedix , ... device companies cost effectively improve their time-to-market, partnered ... the company,s refractive cataract surgery laser system. Designed ... critical manual steps in cataract surgery, the LensAR ...
... Officer of the American Telemedicine Association, has shared ... telehealth in the immediate future.  These trends represent ... challenges and opportunities for the industry.  ... 1. A Shift away from reimbursement models ...
Cached Medicine Technology:Cogmedix Provides High-Precision Subassembly for LensAR Revolutionary Refractive Laser 2ATA CEO: 7 Market Trends Shaping the Future of Telemedicine 2ATA CEO: 7 Market Trends Shaping the Future of Telemedicine 3
(Date:3/6/2015)... 06, 2015 “On Tap” takes the audience ... grand stage, to the silver screen and to modern day ... toe-tapping numbers and their famous eye-high kicks! Producers, directors and ... history of tap dancing in this robust show, showcasing one ... the United States. , “On Tap” is proud to ...
(Date:3/6/2015)... San Rafael, CA (PRWEB) March 06, 2015 ... the addition of three Maryland camps – two non-contact ... camps will be run by Perfect Performance Training, located ... camps will focus on developing position specific skills, speed ... will be hosted at Salisbury University with Marvin Graves, ...
(Date:3/6/2015)... At Natural Products Expo West, Makeena, ... of its powerful, location-aware iOS app that helps ... at any retailer that carries those products, including ... Booth 6054. , Makeena’s proprietary algorithm allows ... Paleo, and vegan, among many other product attributes. ...
(Date:3/6/2015)... Johnson & Johnson and Ethicon were hit with ... in Superior Court in the State of California in ... 12 awarded Mrs. Perry $700,000 in actual damages for ... TVT Abbrevo plastic sling for stress urinary incontinence. The ... $5 million in punitive damages. , According to court ...
(Date:3/6/2015)... First Choice Emergency Room opened ... is located at 13351 W. Bowles Avenue, Littleton, Colorado and ... ready 24-7 to provide the highest quality emergency medical care ... of First Choice Emergency Room Littleton. , First ... Metro Denver Chamber of Commerce and a medical community open ...
Breaking Medicine News(10 mins):Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2
... inclination, study finds , WEDNESDAY, June 17 (HealthDay News) -- Bad ... violent street gangs. But a new study finds that the urge ... genes. , Boys who have a variant of the gene monoamine ... are not only more likely to be in gangs than boys ...
... , - SLA Centennial Observance ... Century , Elsevier has been awarded ... BioMedicine and the Life Sciences" at the Special Library,Association,s (SLA) ... published by Elsevier, many on behalf of renowned,societies, were also ...
... in Health and Life Sciences Category , , SUNNYVALE, ... Incorporated (Nasdaq: ARAY ), a global leader in ... the company,s president and CEO, received the Ernst & Young ... Life Sciences category in Northern California. According to Ernst ...
... has begun , , PITTSBURGH, June 17 Mylan ... subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. ... Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This ... and 30 mg strengths of the product. , , ...
... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... agreement with Deerfield Management, a leading healthcare investment organization and ... funding through a credit facility. , , "We ... the potential of our business and that we have the ...
... the development of TMC207 and the discovery of new ... 17 A new landmark collaboration between the Global ... product development partnership, and Tibotec Inc., (Tibotec), a global ... Health Summit in response to the urgent need to ...
Cached Medicine News:Health News:Boys May Feel a Genetic Pull Toward Gangs 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 3Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 4Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 2Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 3Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 3Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 5Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6
... Angiotensin Converting Enzyme (ACE), also known ... (EC 3.4.15.1) with a molecular weight of ... glycoprotein shows a single polypeptide chain, a ... is present in many different cell types ...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease...
Anti-Gliadin IgA (Ab) EIA Gastrointestinal Markers 027-GD17 Celiac Disease Food Allergy...
Medicine Products: